Study Title and Description
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Key Questions Addressed
|3||Key Question 3. What are the harms of using medications to reduce risk for primary breast cancer? Key Question 3a. Do harms of risk-reducing medications vary by timing of initiation and/or duration of use? Key Question 3b. Do harms of risk-reducing medications persist beyond discontinuation of use?|
Primary Publication Information
|Title||Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.|
|Author||Delmas PD., Bjarnason NH., Mitlak BH., Ravoux AC., Shah AS., Huster WJ., Draper M., Christiansen C.|
|Country||Hôpital Edouard Herriot, INSERM Research Unit 403, Lyons, France.|
Pubmed ID: 9385122
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-4
Results & Comparisons
No Results found.